Merrimack Pharmaceuticals will present the Infotrieve/ELN electronic laboratory notebook as part of its presentation at the upcoming Laboratory Informatics conference in San Diego, California
Infotrieve reports that Merrimack Pharmaceuticals is scheduled to present the Infotrieve/ELN electronic laboratory notebook as part of its presentation titled 'Software Essentials for Systems Biology' on 1 February 2006, at the upcoming Laboratory Informatics conference in San Diego, California.
The conference is produced by the International Quality and Productivity Center (IQPC).
Brian Harms, a senior scientist from Merrimack, will be presenting.
Software Essentials for Systems Biology will provide conference attendees with an introduction to software tools that enable systems biology which will include an overview of the applications and benefits of the Infotrieve/ELN electronic laboratory notebook.
Harms will show how Merrimack uses the Infotrieve/ELN, the MathWorks Simbiology environment and Teranode's Protocol Modeler in concert to advance Merrimack's research.
"The Infotrieve/ELN is an ideal electronic laboratory notebook solution for biotech companies like ours," said Birgit Schoeberl, Merrimack's director of network biology.
"The Infotrieve/ELN offers robust data storage, enables rapid and secure data searches, and supports biologists as well as chemists." Merrimack has been an Infotrieve customer since 2003.
A case study on Merrimack's use of the Infotrieve/ELN can be found on Infotrieve's website.
Infotrieve is a provider of specialised search, electronic laboratory notebook software, pay-per-view content services, and content management technology.
The company supports the research and development work of leading corporations within the life sciences and other R+D-intensive industries that pioneer important scientific, technical, and medical (STM) breakthroughs.
Infotrieve was founded in 1988 and has offices located throughout North America, Europe, and Asia Pacific.
Merrimack Pharmaceuticals is a privately held biotechnology company focused on the discovery and development of novel treatments for diseases in the areas of autoimmune disease and cancer.
Its lead compound, MM-093, is currently in Phase 2 clinical development to treat patients with rheumatoid arthritis or with psoriasis.
MM-093 is an investigational drug and has not been approved by the US Food and Drug Administration or any international regulatory agency.
The company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and safe therapeutics.
Merrimack is based in Cambridge, Massachusetts.
